ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an clinical-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
To achieve these goals, we have established several proprietary platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells, to fulfill the cancer-killing tasks. Macrophages play critical roles in fighting cancer through phagocytosis followed by tumor antigen presentation to T cells, which in turn destroy antigen-expressing tumor cells. However, cancer cells have evolved to evade immune surveillance, by mechanisms such as over-expressing CD47 and inhibiting phagocytosis via interaction with signal regulatory protein (SIRPα) on macrophages. We are developing a pipeline of compounds for reversing cancer cell-induced inhibition of innate immunity.
NK cells are innate defense mechanisms of the body against viral infection and cancer, which directly target pathogenic cells without requirement for MHC recognition. We have established proprietary platforms and target-activated NK (TANK™) cell therapy for treatment of both leukemia and solid tumors.
ImmuneOnco is actively advancing pipelines of proprietary platform-based compounds targeting a broad range of canncer indications.
Rating Reviews
Rating is calculated based on
1
review and is evolving.
Pros: I've really valued the chance to work on cutting-edge projects in the pharmaceutical industry here. The R&D team is full of smart people, and there's a genuine culture of learning and sharing knowledge. It's a dynamic environment where you can see your contributions directly impact research goals. The company offers solid opportunities for hands-on experience and professional development for those eager to grow their careers in biotech.
Cons: Sometimes the project timelines can feel a bit ambitious, leading to crunch periods, especially when dealing with regulatory submissions or tight deadlines common in drug development. Streamlining some internal approval processes could also help improve day-to-day efficiency. It's not a deal-breaker, but these areas could enhance the overall work experience for the team.
Advice to Management: Consider further optimizing project management tools and communication channels to better manage workload during peak periods and accelerate internal approval processes. This could significantly boost team efficiency and morale.
Show more
What is the typical salary range for a research scientist at Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. in the competitive Shanghai biotech industry?
As a research scientist at Yiming Angke Biomedical Technology (Shanghai) Co., Ltd., I've seen salaries for roles in Shanghai's vibrant biotech sector generally range from 20,000 to 35,000 RMB per month, depending on experience and specific responsibilities within the R&D team.
CN
